1252 related articles for article (PubMed ID: 28813417)
1. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.
Burr ML; Sparbier CE; Chan YC; Williamson JC; Woods K; Beavis PA; Lam EYN; Henderson MA; Bell CC; Stolzenburg S; Gilan O; Bloor S; Noori T; Morgens DW; Bassik MC; Neeson PJ; Behren A; Darcy PK; Dawson SJ; Voskoboinik I; Trapani JA; Cebon J; Lehner PJ; Dawson MA
Nature; 2017 Sep; 549(7670):101-105. PubMed ID: 28813417
[TBL] [Abstract][Full Text] [Related]
2. CMTM6, a potential immunotherapy target.
Liang J; Li S; Li W; Rao W; Xu S; Meng H; Zhu F; Zhai D; Cui M; Xu D; Cai J; Zhang B
J Cancer Res Clin Oncol; 2022 Jan; 148(1):47-56. PubMed ID: 34783871
[TBL] [Abstract][Full Text] [Related]
3. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.
Mezzadra R; Sun C; Jae LT; Gomez-Eerland R; de Vries E; Wu W; Logtenberg MEW; Slagter M; Rozeman EA; Hofland I; Broeks A; Horlings HM; Wessels LFA; Blank CU; Xiao Y; Heck AJR; Borst J; Brummelkamp TR; Schumacher TNM
Nature; 2017 Sep; 549(7670):106-110. PubMed ID: 28813410
[TBL] [Abstract][Full Text] [Related]
4. Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation.
Xu X; Xie T; Zhou M; Sun Y; Wang F; Tian Y; Chen Z; Xie Y; Wu R; Cen X; Zhou J; Hou T; Zhang L; Huang C; Zhao Q; Wang D; Xia H
Nat Commun; 2024 May; 15(1):4237. PubMed ID: 38762492
[TBL] [Abstract][Full Text] [Related]
5. Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody.
Jia XM; Long YR; Yu XL; Chen RQ; Gong LK; Geng Y
Acta Pharmacol Sin; 2023 May; 44(5):1095-1104. PubMed ID: 36418428
[TBL] [Abstract][Full Text] [Related]
6. CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.
Miao B; Hu Z; Mezzadra R; Hoeijmakers L; Fauster A; Du S; Yang Z; Sator-Schmitt M; Engel H; Li X; Broderick C; Jin G; Gomez-Eerland R; Rozeman L; Lei X; Matsuo H; Yang C; Hofland I; Peters D; Broeks A; Laport E; Fitz A; Zhao X; Mahmoud MAA; Ma X; Sander S; Liu HK; Cui G; Gan Y; Wu W; Xiao Y; Heck AJR; Guan W; Lowe SW; Horlings HM; Wang C; Brummelkamp TR; Blank CU; Schumacher TNM; Sun C
Cancer Cell; 2023 Oct; 41(10):1817-1828.e9. PubMed ID: 37683639
[TBL] [Abstract][Full Text] [Related]
7. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.
Zhang J; Bu X; Wang H; Zhu Y; Geng Y; Nihira NT; Tan Y; Ci Y; Wu F; Dai X; Guo J; Huang YH; Fan C; Ren S; Sun Y; Freeman GJ; Sicinski P; Wei W
Nature; 2018 Jan; 553(7686):91-95. PubMed ID: 29160310
[TBL] [Abstract][Full Text] [Related]
8. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.
Zugazagoitia J; Liu Y; Toki M; McGuire J; Ahmed FS; Henick BS; Gupta R; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
J Thorac Oncol; 2019 Dec; 14(12):2084-2096. PubMed ID: 31605795
[TBL] [Abstract][Full Text] [Related]
9. HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer.
Liu Y; Li X; Zhang H; Zhang M; Wei Y
Oncogene; 2021 Mar; 40(12):2230-2242. PubMed ID: 33649535
[TBL] [Abstract][Full Text] [Related]
10. Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1-Independent Manner.
Long Y; Chen R; Yu X; Tong Y; Peng X; Li F; Hu C; Sun J; Gong L
Cancer Immunol Res; 2023 Feb; 11(2):241-260. PubMed ID: 36484740
[TBL] [Abstract][Full Text] [Related]
11. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
[TBL] [Abstract][Full Text] [Related]
12. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma.
Yugawa K; Itoh S; Yoshizumi T; Iseda N; Tomiyama T; Morinaga A; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
Hepatol Commun; 2021 Feb; 5(2):334-348. PubMed ID: 33553979
[TBL] [Abstract][Full Text] [Related]
13. TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity.
Ren Y; Qian Y; Ai L; Xie Y; Gao Y; Zhuang Z; Chen J; Chen YX; Fang JY
Nat Commun; 2021 Sep; 12(1):5405. PubMed ID: 34518538
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours.
Yao H; Lan J; Li C; Shi H; Brosseau JP; Wang H; Lu H; Fang C; Zhang Y; Liang L; Zhou X; Wang C; Xue Y; Cui Y; Xu J
Nat Biomed Eng; 2019 Apr; 3(4):306-317. PubMed ID: 30952982
[TBL] [Abstract][Full Text] [Related]
15. Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma.
Liu LL; Zhang SW; Chao X; Wang CH; Yang X; Zhang XK; Wen YL; Yun JP; Luo RZ
Cancer Immunol Immunother; 2021 Feb; 70(2):417-429. PubMed ID: 32770259
[TBL] [Abstract][Full Text] [Related]
16. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen J; Jiang CC; Jin L; Zhang XD
Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
[TBL] [Abstract][Full Text] [Related]
17. Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma.
Chen L; Yang QC; Li YC; Yang LL; Liu JF; Li H; Xiao Y; Bu LL; Zhang WF; Sun ZJ
Cancer Immunol Res; 2020 Feb; 8(2):179-191. PubMed ID: 31771985
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.
Tu X; Qin B; Zhang Y; Zhang C; Kahila M; Nowsheen S; Yin P; Yuan J; Pei H; Li H; Yu J; Song Z; Zhou Q; Zhao F; Liu J; Zhang C; Dong H; Mutter RW; Lou Z
Mol Cell; 2019 Jun; 74(6):1215-1226.e4. PubMed ID: 31053471
[TBL] [Abstract][Full Text] [Related]
19. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
[TBL] [Abstract][Full Text] [Related]
20. The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity.
Ho P; Melms JC; Rogava M; Frangieh CJ; Poźniak J; Shah SB; Walsh Z; Kyrysyuk O; Amin AD; Caprio L; Fullerton BT; Soni RK; Ager CR; Biermann J; Wang Y; Khosravi-Maharlooei M; Zanetti G; Mu M; Fatima H; Moore EK; Vasan N; Bakhoum SF; Reiner SL; Bernatchez C; Sykes M; Mace EM; Wucherpfennig KW; Schadendorf D; Bechter O; Shah P; Schwartz GK; Marine JC; Izar B
Cancer Cell; 2023 Jul; 41(7):1207-1221.e12. PubMed ID: 37327789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
